0001213900-24-052776.txt : 20240614 0001213900-24-052776.hdr.sgml : 20240614 20240614133821 ACCESSION NUMBER: 0001213900-24-052776 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240611 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240614 DATE AS OF CHANGE: 20240614 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IMMUCELL CORP /DE/ CENTRAL INDEX KEY: 0000811641 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 010382980 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12934 FILM NUMBER: 241044050 BUSINESS ADDRESS: STREET 1: 56 EVERGREEN DR CITY: PORTLAND STATE: ME ZIP: 04103 BUSINESS PHONE: 2078782770 MAIL ADDRESS: STREET 1: 56 EVERGREEN DRIVE CITY: PORTLAND STATE: ME ZIP: 04103 8-K 1 ea0207919-8k_immucell.htm CURRENT REPORT
false 0000811641 0000811641 2024-06-11 2024-06-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) June 11, 2024

 

ImmuCell Corporation

(Exact name of registrant as specified in its charter)

 

DE   001-12934   01-0382980
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

56 Evergreen Drive Portland, Maine   04103
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code 207-878-2770

 

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of each exchange on which registered
Common Stock, $0.10 par value per share   ICCC   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 

 

 

 

 

Item 1.01. Entry into a Material Definitive Agreement

 

On June 11, 2024, ImmuCell Corporation (the “Company”) and TVP, LLC (the “Landlord”) entered into a Fourth Amendment of Lease (the “Lease Amendment”), which Lease Amendment amends that certain Indenture of Lease, dated September 12, 2019 (as amended to date, the “Lease Agreement”), by and between the Company and the Landlord with respect to certain property leased by the Company from the Landlord located at 175 Industrial Way in Portland, Maine (the “Leased Premises”).

 

The Lease Amendment revises payment terms set forth in the Lease Agreement for amounts due by the Company to the Landlord with respect to certain tenant improvements on the Leased Premises. Pursuant to the Lease Amendment, in lieu of a one-time rent payment of $488,743 previously due in July of 2024, the Company will now make additional monthly rent payments of $20,000 from July of 2024 through December of 2024 and a one-time payment of $368,743 in January of 2025.

 

The forgoing description of the Lease Amendment is qualified in its entirety by reference to the Lease Amendment, which is filed as Exhibit 10.1 hereto and incorporated herein by this reference.

 

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

 

The information included in Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 2.03 of this Current Report on Form 8-K by reference.

 

Item 9.01.  Financial Statements and Exhibits.

 

(d) Exhibits.

 

10.1   Fourth Amendment of Indenture of Lease for Premises Located in Portland, Maine between the Company and TVP, LLC dated as of June 11, 2024.
104   Cover Page Interactive Data File

  

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  IMMUCELL CORPORATION
   
Date: June 14, 2024 By: /s/ Michael F. Brigham
    Michael F. Brigham
    President, Chief Executive Officer and Principal Financial Officer

 

2

 

 

Exhibit Index

 

Exhibit No.   Description
10.1   Fourth Amendment of Indenture of Lease for Premises Located in Portland, Maine between the Company and TVP, LLC dated as of June 11, 2024.
104   Cover Page Interactive Data File 

 

 

3

 

EX-10.1 2 ea020791901ex10-1_immucell.htm FOURTH AMENDMENT OF INDENTURE OF LEASE FOR PREMISES LOCATED IN PORTLAND, MAINE BETWEEN THE COMPANY AND TVP, LLC DATED AS OF JUNE 11, 2024

Exhibit 10.1

 

FOURTH AMENDMENT OF LEASE

 

This is a Fourth Amendment of Lease (this “Amendment”) dated as of this 11th day of June 2024, by and between TVP, LLC, with a mailing address of P.O. Box 66749, Falmouth, Maine 04105 (hereinafter the “Landlord”), and ImmuCell Corporation with a mailing address of 56 Evergreen Drive, Portland, Maine 04103 (hereinafter the “Tenant”).

 

WHEREAS, the parties entered into an Indenture of Lease dated September 12, 2019, as amended by First Amendment of Lease dated June 15, 2020, as further amended by a Second Amendment of Lease dated August 15, 2022, as further amended by a letter agreement dated April 6, 2023, as further amended by a Third Amendment of Lease dated November 13, 2023, (collectively, the “Original Lease”); and,

 

WHEREAS, the parties now wish to amend the Original Lease to adjust the Tenant’s payback for the funding for the certain Tenant improvement to the Demised Premises;

 

NOW THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree that the Lease is hereby amended as follows:

 

1. Capitalized terms not defined in this Amendment shall have the meaning ascribed to them in the Original Lease. The Original Lease, as amended by this Amendment, is the “Lease”.

 

2. In lieu of the Tenant’s payment of $488,743.00, due July 1, 2024, Landlord has agreed to accept payment as follows:

 

Payments for Tenant Improvements

 

Date  Amount 
July 1, 2024  $20,000.00 
August 1, 2024  $20,000.00 
September 1, 2024  $20,000.00 
October 1, 2024  $20,000.00 
November 1, 2024  $20,000.00 
December 1, 2024  $20,000.00 
January 1, 2025  $368,743.00 

 

For avoidance of doubt, the amounts set forth above are in addition to all other amounts due under the Lease.

 

3. All payments are due without demand or offset, on or before the first day of the month, and all other Rent payments due under the Lease must be kept current, or this Amendment becomes null and void.

 

In all other respects, the terms and conditions of the Lease are hereby ratified and affirmed.

 

 

 

 

IN WITNESS WHEREOF, the parties hereto have hereunto set their hands and seals on the day and year first above written.

 

  LANDLORD: TVP, LLC

 

Witness:  /s/ Karen Twohig   By: /s/ Richard McGoldrick
        Richard McGoldrick, Manager

 

  TENANT:
  ImmuCell Corporation

 

Witness:  /s/ Jennifer Turkewitz   By: /s/Michael Brigham
        Michael Brigham, Duly Authorized

  

 

 

 

EX-101.SCH 3 iccc-20240611.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 iccc-20240611_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 iccc-20240611_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
Jun. 11, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 11, 2024
Entity File Number 001-12934
Entity Registrant Name ImmuCell Corporation
Entity Central Index Key 0000811641
Entity Tax Identification Number 01-0382980
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 56 Evergreen Drive
Entity Address, City or Town Portland
Entity Address, State or Province ME
Entity Address, Postal Zip Code 04103
City Area Code 207
Local Phone Number 878-2770
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.10 par value per share
Trading Symbol ICCC
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://immucell.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea0207919-8k_immucell.htm iccc-20240611.xsd iccc-20240611_lab.xml iccc-20240611_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0207919-8k_immucell.htm": { "nsprefix": "ICCC", "nsuri": "http://immucell.com/20240611", "dts": { "inline": { "local": [ "ea0207919-8k_immucell.htm" ] }, "schema": { "local": [ "iccc-20240611.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "iccc-20240611_lab.xml" ] }, "presentationLink": { "local": [ "iccc-20240611_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 22 }, "report": { "R1": { "role": "http://immucell.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-06-11", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0207919-8k_immucell.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-11", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0207919-8k_immucell.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://immucell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001213900-24-052776-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-052776-xbrl.zip M4$L#!!0 ( ,ILSEC 4AOBVA, /%M 9 96$P,C W.3$Y+3AK7VEM M;75C96QL+FAT;>T]:7?:.M/?^15ZN5MZ3@#;$ (DY3D$2$HV4DB;-%]RA"W MC;=Z8>FO?V=D&VPP60BTZ;WMN3$? MP@S95%1C\/Z?6K?>:OWSOVKJ<.A"-^AJ.._30]>U*KG<>#S.CO-9TQ[DQ'*Y MG)M@G[3?J3))["<)@IB[O3CORD.FTXQJ."XU9#8;I*G&PVKXV#KKVK,U-=85 MGX1(\KDET-"JS =$.Q=S?F.LJYO8=<_OZH9=5<-L0&.[2Z#AH>Q3JUZO3[K MI>JZ)S--R\JFSGL)15%,HVXQJE13!/\=NJJKL>IASO^=.M292PD"R+!OGCIZ MGZZ;ALL,-W,]M8#5LO_M?=IE$S?'%3 'HW(^R,/_RV3(LDU> ?[@6I^9Z!4 'Q\%]-9X8"_[O'&AW<]ZGFL!= *D0@-0U8A&D=0-E4:QD* MFYRQZ;T _TJB6"R\@,#B$;"X<2_>!]; AP^/7@!"NN\.J^F>VSX?AL.? MO0 ,+G;C*@"57R)H%>R>J4R)XTXU]C[=!YFK$%&P7'*MZM#CDHU)Q]2IL>L_ MV 7\MMI'T5;443A,41U+H],*,4R#89LZJ:"8,AMDGW]1%849J CX#7I=>CK MD7TAG[@=M!,UI]U'"6 MJBS+F5!1LA-'20?-+EB%]VE'U2V-H24(T,0@^Z@)3J?>.HOS9G'P#%DN"5N RP)&FLH2">#V M;;=!75:=4Q_"F;1YGS41S(W&(A+0<%BX)8;B2"[LU#7M>>N+ MY[Y(7@+,",8&,TQ=-9[ ^20_%I$F@ V;H]-?9&.@>G--\U4^L'F'.1A;3:52 MA]9++>L!T:D]4(T*P:[" 4&QRU!-'< C&;2%V6F((2R 'O4*'4]CF2LZX XQ M:II]:!G7M#C$$'RF9[JNJ0?/QJKB#I$ZX:]T;'3/M&%"_N@CC7%8TD -O>JGRY;U\T&Z5[7KIO=PURO^C;(ZC;KGSJM MZU:S2VJ7#=*\K7^H79XT4_7VQ46KVVVU+]\.K3?4&4(ZZYJ I9&M9U,2!'KE MU]&7A/H9-'-Z0O%Z*_PY;G@P4RT*31\*93,.4/8RB,-^XEV=1 M^CQ>_W[RL4[W.^[YJ0UAPKKA5#D:3D5QIJNES-EB^'280VJK;X>%;VU)03D[ MSM3O7;X>N*\]V/&JX*=<$\#)6&HB8)^T.$?=VE'?$[)/K(<,FSU9= M%Y"TVEH-@I@O&H+%@#*YX]-OT0^-DJW \^7)Z M:K6_>4>#%UD%OP(%*<[$K2@ 78>^0X5.IS K9L2MAB@D68T8<>GJJ6LS"*FC/)D"H0QR+ MR9C8*D0%?KL. 9,&&FF_>ZT1":+8!3%R:4]C!,MQP!$9"_EI4!3\;E%%";^_ M&&4D 9C%]6"2-&HY$+V'GWA^>.C:(?P1LUU5IEK(56!CD$(>NLI""K&0)63W MYGE"@#PO >Y@%AF-]9'TH_9R>NB%4??A\-]7?RR_K+DEY=ECA8+ M7&)&E'BT\A];"B&V%-=TT@HJ>S(7U\?6Q=*:@['35\NE_OH+DU":74$$K)*8 M$?(EJ5P2GK%,\,->Q[QM@,<[7,F):1/3'3*;?(7XV%%4'D$?]FPL]8+;4:-F MX5V2A#TF.*\FJM3JN'=C'DP]V8^^N_XJXMK1R,6(4@),NB$)^B_YY#6<2$(I.U[)! M8%2+:H1-F.RYH/_P&)P*8W@ M[S]*DKA_X, PC5E#TV#$X&'&;@I61O-0'0FU&048"EN_"E8,E 4M9 W K5:/ M&^'#G=+X]*7MOJ(N$BN)1W&FJY*POT(=,HM$'P5$GYN@!5?(G,?B[_S7*]K[ M5KQH2'1MPJ5856X1;[I:VB]EI/W])P/N'RA+6Q??!10_8U,VYD7>Y+;KSC'X MP%@$]%'IS3JA.7M+972-C11U^UF.Z8.?VT_?YA%J3,.V M/J0(YAC'822E8OKF5+9=K(RF/(LIT8M1QC7\F9LN<6UZ-(B(2_!7SX$T.F^W*KJ[L5471 9S<<\( MDETGV0$4]#S+#[63@E=<>]NF9YH:HP8_<;?@&F*U_D2R4#S*^X7"P7/BO>3H M:+8: 0(@/(J!6,$F).H/6C8":A+H@!O;?$SAGN..N$_JQQTBY84L='SG!V<\ MB)I%4)LP%(_ZI-]:LCTM"7/6+KA&&=;=&%R /0:CK"6KB&=VK.O2P_!+9_V= MS4=4)%;M7Z9ID_HQAPX+[8-?5@ZQ0#.B%-&/<$<^KAT%(>OW_*T@_S8%R0<* MQO+%\ M/G#[O6VH4>$1-5JB\.4O,9W^=+2W?RCRYJ]5[?,M\C;)[KWJ-+_3YI_/D M(9$UZCC^4:75!>+9EL'\R,O"IL(+2\@_8IHVY>569ZKW3&T'*^#_ODE>!J>\ M^%*RT 2!VHV'*CR9Z^;BY)^W00$"#C0/;!/L7":P,_:@MR,)A5TI7]J5]O;> M;6(38U5].S S4U'J<:E-=DM2.2](CGC[N558OU0%;/&OLTFU]\V75>?I 0;I]WU[I1RZ:Y^ M5UZ?L[$-WAC2=!5?V7V+/,.CWZN2CU X0H^_^E#J]**F-$J%:V_\LKW)Q9UD M5.RD361I/TEHHW2EP4(X"OVVZAA G5JJ"[GV!;4?F+O=O;FG/?:6@I66H6 H MQTAO2F1>\891#V B&3_ !#]2D5.RJD-@V2$.1, # L9O[ XQ(K2P+$T=HK"^ M:O@G:/V:G; 75JLC8='\)8$\V<%9[A_PNEW86>5G;RT\>XL[# @I!>8F(R7 M2GKS8 840\SYN C8[':Y^B-6KKEB%3:6#\6/O83H3CBVNH]LQ=&7]H4SN1HQ M9_PRR_C,5"CA0$(B<<_.@GYU26CU']'*7=#%!15/<14/]J\BVCT$!68:Y":@ MP(;),Q7/8;P7H TVL_#^$95G+_[+U;AJ')1C%5"C&!HP(VBQV4AU8!R8 M!6K(6+JD,K^H SJG\/(7A=J*XV]@*:O2I/P.?1>J?E3?LP%WUY7XF7QL4A#\ MG]G-KWX4\,_'(:\4_>?_Z)ZT$SN QGWSL&8"X/ET>-BUS-A'SI!% M%TZ4$E:NR"-8*[[02V\L!6^P+^&W&7W(]!BH+]!H<9JC&(L)")&*%V*,KN^O ML+0\U$,0L:>+K&KB7;Q)*PMT=TL P1^5GR&IXH!0+8YMXW7 [QQO2 MU;9!8B_8[9*D=[7(CG\@H21)PD'@1/DW\>!="BPUN?Y\M4O.S^NQCN?0 LFO M$O8D/(G@,2!GVK'IV> 39A>]H"$_9Q0<2PP*?S+K% +;#9+UA>84Q4\.. 3J M0M9BNQ0"SA9WBY[-9AAV";Z;J !3(.C#8TT@P<@ L4QVP-=Q(/X!#>RW2Y;I M"1=W3@\X461%C[ECR#EX>;,>QK_P'+^''/&=HAR09LI\(C!;<7\/9^J!ST9)O*$HG:GP"/ NX0=BEUFKD"N;Z>"* MG7 JFPJ!-RZLF%\NK'<01D"<0*?\.TB8[A"'N1A^ ).!J>Y\6+AJ*8Q-J([A M!J0F'EMD-"S)L]8+8A^>_>@8IG#(#M:19ACGS,V2JT@ ,^N0FLT$PS&BJ-'@'Q%CLYGK()" M&^88./K \$06#]1 2OCKN=HT%<7"3\7^*0F[$%/[(A<%#'!MTQL,P=3)ONJ$ M#2CE$<*C-.>+/LU()#4\:H?@]MZTL(&4#$P,7A7FR+9J1<]?+0HBY)#?/*I% MWQ--X=LI-@-U!O&:W>$46W\267_?H &2XW%MVQRATJC&[Q9'XYY]] M@9K%'K.:1=VSN=X&%PC@.UHP,E7*G/G'#"-"PETN'S1C_1-@\.AB3&[?O#R5 M,2[S84<$B+\8XILU5)U I9SLUL1@6Y=*I*L[+[D#(IQHD,,&J_??>UM]O=V8 M 'WYKZ=JWFB:G[$_)C[^WE"(3G@2WR$E_AV"C J2L%\6RX+()J*0$>>7> Y= M/5U-BJZ7 V%>I EC%'(>1)-@;1;CQB"L)8MA[2SR]P-JRH.'6$H!DDF\-SW5)^ 5(?@SN;I.[ 0(DPJ\PRO05W*7XM]= M@:7)LY'C%4FPE&\=O9OK9EL^&JDQZ\U[%6[K9/+VO6G3G/KR+9;8^0UU*FD>,L.;+5P9#J&^-=XK,?C0_B M)X???KQ+ZD.5]2')"%\D;O,7B6T>*EW-7C2.I+=^^]9>[-V&87].Y)#_=P<) MTG\B2/A%;UKD^,/2&;_-_0U=./GK^,87F_V55UK,5^/2S,YY:CY M_^X]#>L+R_:"PY5_SJ9T=,_/C_$+"N9_!8>=3HZ_*L+9X*'V<7B7JRF3K]*- M=G9;'[6FSI>!\U$]*][>GEV<*E)'8OG1PZU]_EG]1(_,WM!HE^36I[.)97WV M'MHGI?.:4_CB.N)4/?ET4V]_]>A1_N[4=>NCX@V[O+UQKD\]]J$\Z%A[1]]+ M8_V35BQ=' _ZDG[V^>/7Z=6#_O!@[35:RCFMC85"Z,;G0:/U M^GG=Q#X^*A\+#?UH>&\S%? M%VXZ:K3TZ[UY;W/D1S^\1[^ M1Z%<7:O^/U!+ P04 " #*;,Y8Q&K]M.<' !(*0 '@ &5A,#(P-SDQ M.3 Q97@Q,"TQ7VEM;75C96QL+FAT;>U:;7/:.!#^GIG\!QUS[;0SYCW0E%!F M2( K/0(,N)>YC\(66!=C<;*<-/WUMRO98 A0::)H#E?7MVM=(C4_]H M7_8:QT?UC^UF"UX)_JO;7;O7;M3SYA5&\_%P_7S0^I.,[3][[0^9J0A4C10+ M"T5L/F56(!,(IZ="*7$7%])VW!8H)C, M-%X'DW!Q=E_9H7$L[1BS"W7?,%[;9KHS^#RR/Y+F9;O?@E^;##JDUVZ.VS_$ MF\<"0IM8HLT#EZ%\(5?A0:9A>SPD\)^2CHBD\DASS@(7?A414])C-&3DC<*; M7OONWY$X6XZ_EOKSV^,CERKF$AJBA+ZU6*R//P\;RJOG\96X] ['/D4!(Z5" MZ<0BDSM" Y=,F+IE+"#V'T.+]'H7%KGEX ,%S[G/@QFAKBM9J#4/1:YI#Q@QT>%DV*A0MYX3#(>T"E@"-ZPQ.\>V/.%=!.W M+>U =SZ/+ICODPLA%T)2Q46PQX=*E;1OF)Q)=+HE^0VSR%!(Y8.N-3_*._VP M64!7X.4>+;W_4;U8H*"[_SDJ7S@#:,%24;S0D)72&A6R]B#H*Q"U,OM C6$:( MF1Y-PCX^,LCAH/L79@]'D_D4(A@AJ+J;4.>:3(69==,H<'$2)Y\=)A5,TUB, M\/E"8@HPL: 7[VBQ.0\A-4.IWX2/A\2C0YMI] =7Q$8H.X-1VX()2*#N0^ZR MN)7ICLS(/%(1U(T#H6+8(=Z%,$"8IDU9QT?8#A$EH:MX)H2K.^0-]2,Z\=FZ M8I,WR1S&P1&\+XRF4^YP%CBZU]]ZW/%P84'].!6<:\BNS]P9<]>3CC=@2G&" MP0"%28+#)M\HQ7ITRC%"/<#8C/6924^OU^D"PCOYZ;]ALM;K]WSYD"AG]>3QL7B2?8Z,3P)O)+"YY=!$RV/S&[\Y@ M(7"5APX57IV1AY 89$:CQ #LUA1WJ)]LKLVN.Q-SJ+K=VO DV96?^[B*%',5 ML!@*G[N:\K1@T394QVXU4L(+V"/"+%U*:SDMD8 3RZS,7@P0C_Z'3&D3C)TN M;*<)8*0)&^% ?9=C\&=T&'9G!!?8F023+B9.2."'L\F;4N'$*I5/K5*E\G8+ MOG$Z3T]?91KI>;?I<9+V5ZO"6L-M\[9U4'PVA?!^W:'T_<;=FM9")RE8A4(! MVL).7[8927GW?>!=>5RQ%&*-9&^Z#M!>. [ X"&!/V&T>TJED6('+S+V>YD> M.$J\W'#WI7I%?%YDZ/N;,$=@I$$$VC7MAGP^:ZR!=JV0 MD"Q<,$>%IN@,S\4H\!!.UU>8 &EPP9P87G]\A <*4\[,:0.= O1SM@K=_#S1 M(=1_[=/KKIVOST>$WW8.>AL/??2)SWX'CJN.#["1@UW<0D#@6MF41X%-;KW<7SSE ML<_75O>\-\B+7P"T(R D4M\-'KPO+S_ .3P9T,'?14K MJ8_OIPC;7'V ]MHXRCR63;A1[N(XL[OF*6:1F9-.IVN%*'4VK:PR<0_Y&_Q MWS1_6W/R1X.7QV]"FJ]&XC-"YG(043+"3A MK&GYCF^_;7?ZG8M<'GQ\0/0O\8GVP8=@FE0!VV.["X;\G/P M'8:X#JXPPP(J+L[!,Z2QL? .H5B %@\CBA76CC12'9PXE0H"MKV'[C-F 1=/ M#]U"=ZQ4).NN.YU.'<8G<,K%JW00#_<3["NH8EFH>3,O^^U'OR42%63W1D;R M;/9 7D9W[$O<^7%-;^_@J?Z[5V_??K[-\>M,5:*SZSZ[FX[2=AFQ(-,8A!+H93#8M4U]6WK3J<#%R*Y[GNR^WO7Z"LU)@?48)>]T$ M]VNUFIMX,>0(D+9>TE._"$20496L$'JB L@T_W@@5(T+32XY)8+A?@(6$D"9UMD ]LLR^Q*5,?$V;#70>7E6*) M@SMVD9PC@:6F)R7UM"'C9Y#=7 0IBNE1U$5^NYB9/7^1I3><+](#'H)D >MF M5)J6).8*M#+;6.!ATR(((3OOYR]=MJ-'*8>8"#L6,.G1^IO* N<24*"22NF" MT"(\PD(1/<]+MT":.E&&?K\4!I@XT@+N/ZRP_ 7YBQP2F8.2 M6&EGH(1K)(QHQ=9]K/K;TWF/F3S+HX8 \9@I,3]D$)8I^<-QW5A\^_=K1(Y/ MFV#^'3@V[!%34 Z^:00:;JJFCW\ 4$L#!!0 ( ,ILSEA7A5WL_@H ("& M 5 :6-C8RTR,#(T,#8Q,5]L86(N>&ULS9U=;^.X%8;O"_0_L.Y-"XSC MB;,MD.QD%QE/LC VFZ2Q9[;MHEC0$N,(H41%FB>"0E14G.Q8Q' M? _U4GQ,4E_'GW[<;2AZ(2)-.#L?'1]]'"'"(AXG;'T^^KH87RQF\_D(I1EF M,::$"]WPB+N?AZ/Z_J?O)$1?KR?3CQ^/)/W^Y7D2/9(/'"5/'+2(C':5JL<4= MGYZ>3O)2+6TI=RM!]3Y.)MI.5;,L33KT-2=I3//LOVS1"E-% FCT=$PN-+ M]C[79K0G^_*[([+_H0'U>.=-6/(,TW>9KTRT\-BV27R0F,Q-JDJJ)C!,[WD$\,9=U5[3QJU$O5 M:,Y%N^UJ9LSK3$ETM.8ODY@DLN[I=^K#6'W(FRW_\_N,RY7 Q2K-!(XR75/> MC/.1I7QB6E+*"Z%]81'U-*Y43"(NIZ;G;$R+PUB$/PB^L>ZV;#6W%/Y.5U5\ M<5CD+@"C#9D@*=^*B+RI5^INH:-4.MI0J5!+*L+&7Q>C'W(-^DVK_O-IKF+R2-1/*LEO-=[6C(G'>ZQ62K M[VN:L!!H&X-)J&D]#>SW9)VHJ4594.>W1&WL&,8 O>NAO].V.1=8Q4% ,\0A M.%O4@U 5Y8FC"\:VF-Z39RZZ\&G*7%-C,VG"4M<$Q8C%&(A&H46%V!,1_]C* M,W8BZ+X7BI;2-1> 51,-0Q84'79O(""5W"\C2X%9FJ@!K!>2MM3YZ09@MG7J M8>B"X@0P!Y^25'J_I"P>":7J?@!F_0.*3>R:%MBPR4M;&10QH#V0F3P"E2'A M8'/YHE;GKN2VM*-Y%JUK0$"[)B0M85"@0.Y 6(H S4P>XA68?Q$LAN%24_J!I675 MCDHE"Q 4TUL?)DKO!9+95HB&:WC&@:7.;LKVF*WNSP*Z($#I,=>Z:UO(&Z!X MFH$N699D>_4\W! N *9.!0H:4#A5"+SVO[Q*P M3#W$"#;'E+DEP&ZR24%3$Q )5F, #0=M_DRI%R)F2)=[-8PEJ\I 4SX/W4 +JW<+28[O)#" .")UNAP!!,@@U MHWR"-&<1%\^\]KC#C&_E +B?\1A>H?1$N85J4!.::'6&! 38$)\ 9HW0#\4S M*8BK]WCR"I"JP0MQ%W$L#U1:_G.=,'(,MM^J=4M7A]TF4Q9A0"3![@!^2N4' M_0&I&'3+0H%F^H:F3OU#,QT*S31H:*;O@6;YR@.!YN0-33WQ#\W)4&A.@H;F MY%W0R([W.M;,Y,=;L>2OMH>S0:479-I6K< <9.'ATO+6!XL*4.L9%>(3DWQA M=2ON!'])6 0OF2&Y%V TU9J#&UXZ-@-]O%3+8AUG->QIEB4]WY)M,S/*-,T M:1]B"DUXD#2-]0XNA=HG$G<\S3#]=_+<>2)N%WO!PVK8"DE#&1XJ-GM]P!0Q M2 ;Y.+$N<54W-*RODAGE[EX!MM@ZO )<*PP" INC]BO Q=630N2ZFQ6C@F!@ M1&@6.^MDBZFJCVME871QVU"KA_/OM=3X^"*K["[T[I$S^ &!ML153T/F=&^; MY4'T.&#*[/5M=TTYJF=;GCWOQ5 M))G<\XQO-EM6WN6Q/3<(Z%SU-641"]W^7,)*'4HJ;8,18+3I,HR1*V M_D6>?(H$VUIE$[D" C:H:6@K@D !M&5R"'A,&6M^QXDREYQ>;?/]7\H.EE8#.64[++IM54DN;* A&NIRUTEH62>=J8J34 MKKG8QDE&XL+,5<(PBQ),J_2(MBOB_2'.:!EHO@*G1Q\&0\-,MG JPG0NPRKP MD.K2]:7TX@&,7PFE/S/^RA8$IYR1N+B68KM3U*UW^\1,C^WF0S. . B,G%85T6'DES M)WSC=L@R+_%UR81N9 )U;<@";36(,44"DV)T!A%1B M5*C]O*!=9(^H%EG%[PZ!#83DCE_7[C1MO+5MU0;$3*=!Z!WN,N?'86U<1'EZ MQ3(CZOX] :V%Y*[?JFRR[3Y-J5-&Q!"G0;!]R>K&)4J!FNFO*6, M$3.YU%KSCJ?$#97[Q#$MB^W<,94D(#QLOCHRR BDM5Y86&PPI9^W:<)("D]$ MALHM"U:+318:DH!8L/D"6,BE2&N]L'"Y(6(MI[>?!'_-'LO\K&#; +5;-CHM M-QFQ2@-BILL-S]"2HZ\I0=DC09?ES]#5,\$7]?CZI9$H4B]$%*MR%F-A0ZA+[/Q7 M1T##K=\>:2F# *G7'OP[)%4$TB&.J;F5#(OZ>5QN8IZ1#?BV0W^(*X*&FM<< M]>F#H&F@29.I/*QY48_@J2T/C.&->VYZ1+.\@"(B MBLH15XN1+G22_]_QNQ) M;)^S:'\G>$2(>LHJK4:KONMO Z/=,O.F)C5I&A0:$&=O\0L0>*@"U>KX4)NQ M?%[,4P^-JVQN/'I:/&)Y &^W6:IF4&D,O@K>&>3X]L* !A@W&3HB D)O@$WH MAD,>B?+0#Z@(1K5H3^=GZ2$+((D_[^_) Q'JO8,EV66?Y8Z>.LXP!L2Z/GL; MW!SS9*XW, @(W^H6.M5+4;T"M%+/B)55H-]4)2BOQ?;[Y?5-U_*3W*PWR;]6 M."5RRW\!4$L#!!0 ( ,ILSEBG=YW'5@< -57 5 :6-C8RTR,#(T M,#8Q,5]P&ULS9Q=4]LX%(;O=V;_@S=['4)"VUTH; =2TLF4 DMHN[LW M'456$@VRE)%EDOS[E>PXS8-&6:LLY6JI*M<]/3WMY-^6T@/E[1,XU8)/R>HE6 /;!*YOS9Z MFU9YDF24">$"UG%?=OK*[I"VIWFQF6:3BQ:GE-K:>V^.WW7SNG_?$9G5W.Z8 M*7?[52OJ[+0[URQETN16;^R&G2)L:>SNQ.*R(M<^M&>&&R=>[RS=J.WVK"RQ M;=F/A7+=D;(K0M&=UH6+@-JS6N[-.>>4T:.I>N[$C'>QWZ?MH%UJ&BD=,VU9EW41 M37="=;ACKA6=.=&VHC:=<;&)\D2KQ$=G34)Y.KH-RC;1#,U+VW[L^C 09%J- M>.2PW8'260;P^5;X6WAC&7Q\X#FW+77]<5=[IE M;F-X7/ 4 8(_P1PI@FZ1(G I94;$ YLK70-^5PGD_0:3=Y4W),Q_9T0;IL4* M0OI #(3]%A.VQR$2[T=-9,H='PCP0S60^#O4"P^/1R3DHYF])'8I')&@O;Q* M#\3^!R9VO\]7 /[ZV9W?[:D%SGZK"!#_GZ\%_X%;I C<,\U5;$_I&L#^0 RD M?HI)W>,0E?>UC*&T-U)P_H,/>\\>$NH!3RD118\&=EL:QETAAR)'R3EK;:)B M_Y<1#8:^)88B1TE#:RPV#+R?:;W3F>"HXE=#D:,DH'4F&V9^+0TW*W?/_S9+ MQC]OG.ZR/E1!&:,DG3Y3*&S+.PW2N$<9(;[[2BACE%PS9 Z%<]_ZT40,9JZV;A?W56:/QU5?Q<$AO:8@-!PH^>8+K*,$ MY3*.+:YT_>>&2]8-A:)2#GY&A!> @,U7@KWW,NP].':4/+36YBO!?O(R["=P M["BY:*U-3.Q]^_%./ZJ%YPFT5PQ%CI*+UEC$!)Z?:>[TO5;/O)@354?]H 04 M/6**&C:+NL,7)WG(WEXJH;P1T]5JQ(H7Y1-JJ!<43))GZFF!UXWD3CU'OI;7X-GL*$,J_LV&L;X77-C>]!729+)]3T: MSU,QCQ2*%R7]"]IK&/5("4ZYX7+ZQ5XA:DY$->S.YW&YE0;Z;C+QC;PA/90X2JY7;Q27_#!-,Z9?RK^B%#0**&D?U'33XPRC MF1WV5MW>^-&MF/&,,@_THQKOG@0*%B6SJ[2#-"9<+^F,R"GSSUZH5D(!HV1Z(7-H8^\4-/9. M7SCVHF1\/E-(;(NYX?:(NAL+/B7^E63! N!U-IC$ U:;7K^7+_EQJ[AUDO=C M8#]48_=(H+B4C]TA]];!!H%Q&>(-7910O!-B>SAS+XM)S9MS3_&ZCA!Q7PDH>,2'B&&S2//3#'-]YL_L(S%DW<,0 M?U\)*'_$!XIALVCSYW7?GGBF*OS,?$\(I8TX%;;2&@KD44*$N,I2+ED:'%OV MA%#(B'->*ZVA0+Y.F)[:0>V35@LS6Z_M#,'V%(!"1YS9&K2* W_Y929_>ZGM7_"F0; <-#28BS@!QI&N@M*?"[U8?+5Z8!.F MW32%1[8T5[:AI_!%$: X-#ZH;Q0"8Z@(TWGGP->-W>#>3UM\XWZY=[#:+?\# M4$L! A0#% @ RFS.6,!2&^+:$P \6T !D ( ! M &5A,#(P-SDQ.2TX:U]I;6UU8V5L;"YH=&U02P$"% ,4 " #*;,Y8Q&K] MM.<' !(*0 '@ @ $1% 96$P,C W.3$Y,#%E>#$P+3%? M:6UM=6-E;&PN:'1M4$L! A0#% @ RFS.6-0"!2TI P XPL !$ M ( !-!P &EC8V,M,C R-# V,3$N>'-D4$L! A0#% @ RFS. M6%>%7>S^"@ @(8 !4 ( !C!\ &EC8V,M,C R-# V,3%? M;&%B+GAM;%!+ 0(4 Q0 ( ,ILSEBG=YW'5@< -57 5 M " ;TJ !I8V-C+3(P,C0P-C$Q7W!R92YX;6Q02P4& 4 !0!8 0 &1C( end XML 17 ea0207919-8k_immucell_htm.xml IDEA: XBRL DOCUMENT 0000811641 2024-06-11 2024-06-11 iso4217:USD shares iso4217:USD shares false 0000811641 8-K 2024-06-11 ImmuCell Corporation DE 001-12934 01-0382980 56 Evergreen Drive Portland ME 04103 207 878-2770 false false false false Common Stock, $0.10 par value per share ICCC NASDAQ false